Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research ...

Biocon anticipates a strong second half of FY27 due to US biosimilar launches and favorable regulatory changes enhancing ...

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating ...

With the stock currently trading at Rs 435.45, Biocon continues to be an active player in the Nifty Midcap 150 index.

Firms including JK Lakshmi Cement, Power Grid Corporation of India, Berger Paints, and Bikaji Foods are also to release their ...

Biocon shares gained around 3% after the biopharmaceutical company reported a 348.4% jump in its Q1FY27 net profit to Rs 141 ...

Kiran Mazumdar Shaw, Executive Chairperson at Biocon said products such as Yesafili (aflibercept) and Kirsty (insulin aspart) ...

Biocon Q1 profit surged 348% to Rs. 141 crore as revenue rose 10% to Rs. 4,336 crore. Biosimilars and generics led growth, ...

Aug 5 (Reuters) - Indian biopharmaceutical company Biocon reported a more than fourfold jump in first-quarter net profit on Wednesday on strong revenue growth from its biosimilars segment. • ...

Biocon wins Health Canada approval for Yesintek autoinjector, expanding autoimmune biosimilar options in Canada. Read more.

Biocon's Q1 revenue rises 10% to ₹4,336 crore, driven by a 355% net profit surge from its biosimilars business.

Biocon also reported a 23% year-on-year decline in interest costs to ₹213 crore after measures to strengthen its balance ...